The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in ...
As the first phase of Kenya’s flagship Financing Locally Led Climate Action (FLLoCA) programme ends, its achievements offer ...
The new Phase range covers XC to downhill, with an unusual bar shape and VariGrip versions that can be adjusted without ...
EXPRESS Phase 2 design finalized: 52 weeks of dosing of approximately 60 patients randomized 1:1 to exaluren or placebo, with ...
The BBC needs to make tough decisions due to the sustained financial pressures facing the organisation and must make savings of £500 million by 2028 ...
Aston Villa have added a new player to their List A Champions League squad due to Matteo Ruggeri's injury ...
Cristian Chivu says that his Inter side are not the ‘perfect’ article and insists that he doesn’t want to be described as ...
Correlation between clinical efficacy and changes in inflammatory biomarkers, mucosal transcriptomic signatures, and histologic disease activity strengthens the previously shown clinical proof of ...
First and only biologic therapy to achieve statistically significant and clinically meaningful histologic remission and ...
Disc Medicine (IRON) posted strong APOLLO Phase 3 bitopertin results in EPP/XLP and plans an end-2026 NDA resubmission.
5hon MSN
Capsum changes hands
Chanel has sold its majority stake in the CDMO to Motion Equity Partners, while the founding CEO and management team retain a ...
Braveheart Bio (BRVE) looks undervalued in late-stage HCM with funded Phase 3 trials, strong cash runway and nHCM upside.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results